Summary
Global Markets Direct’s, ‘Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016’, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
The report provides comprehensive information on the Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)
- The report reviews Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Advaxis, Inc.
American Gene Technologies International Inc.
Aprea AB
Cellceutix Corporation
Critical Outcome Technologies Inc.
Eleos Inc.
ORCA Therapeutics B.V.
OSE Pharma SA
PCI Biotech Holding ASA
Quark Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Shenzen SiBiono GeneTech Co., Ltd.
SK Biopharmaceuticals Co., Ltd.
Tara Immuno-Oncology Therapeutics LLC
Z53 Therapeutics, LLC
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) Overview 10
Therapeutics Development 11
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Stage of Development 11
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Therapy Area 12
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Indication 13
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Companies 17
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Universities/Institutes 23
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Therapeutics Assessment 25
Assessment by Monotherapy/Combination Products 25
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Companies Involved in Therapeutics Development 32
Advaxis, Inc. 32
American Gene Technologies International Inc. 33
Aprea AB 34
Cellceutix Corporation 35
Critical Outcome Technologies Inc. 36
Eleos Inc. 37
ORCA Therapeutics B.V. 38
OSE Pharma SA 39
PCI Biotech Holding ASA 40
Quark Pharmaceuticals, Inc. 41
Stemline Therapeutics, Inc. 42
Shenzen SiBiono GeneTech Co., Ltd. 43
SK Biopharmaceuticals Co., Ltd. 44
Tara Immuno-Oncology Therapeutics LLC 45
Z53 Therapeutics, LLC 46
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Drug Profiles 47
Adxs-LmddA159 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AG-1101 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
APR-017 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
APR-246 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ATRN-502 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
cenersen sodium - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
contusugene ladenovec - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
COTI-2 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
D-12PGJ3 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Gene Therapy to Activate p53 for Oncology - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
KM-3174 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
MHY-449 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
MJ-05 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
MX-225 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
N-2 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Oncolytic Viruses to Activate p53 for Oncology - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
OSE-2101 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
p28 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
QPAL-1 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
QPI-1002 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Recombinant Protein to Activate p53 for Oncology - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
SGT-53 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
SL-801 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecule to Activate p53 for Cancer - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Small Molecules to Activate p53 for Cancer and Viral Infections - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Small Molecules to Activate p53 for Melanoma - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
ZMC-1 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Dormant Projects 104
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Discontinued Products 110
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Featured News & Press Releases 111
Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers 111
Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer 111
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002 112
Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients 113
Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer 114
Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers 114
Feb 16, 2016: Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors 115
Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer 115
Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer 116
Jan 22, 2016: Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer 117
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 118
Disclaimer 119
List of Tables
Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Development by Companies, H1 2016 (Contd..2) 20
Products under Development by Companies, H1 2016 (Contd..3) 21
Products under Development by Companies, H1 2016 (Contd..4) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Products under Investigation by Universities/Institutes, H1 2016 24
Assessment by Monotherapy/Combination Products, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Pipeline by Advaxis, Inc., H1 2016 32
Pipeline by American Gene Technologies International Inc., H1 2016 33
Pipeline by Aprea AB, H1 2016 34
Pipeline by Cellceutix Corporation, H1 2016 35
Pipeline by Critical Outcome Technologies Inc., H1 2016 36
Pipeline by Eleos Inc., H1 2016 37
Pipeline by ORCA Therapeutics B.V., H1 2016 38
Pipeline by OSE Pharma SA, H1 2016 39
Pipeline by PCI Biotech Holding ASA, H1 2016 40
Pipeline by Quark Pharmaceuticals, Inc., H1 2016 41
Pipeline by Stemline Therapeutics, Inc., H1 2016 42
Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 43
Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 44
Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 45
Pipeline by Z53 Therapeutics, LLC, H1 2016 46
Dormant Projects, H1 2016 104
Dormant Projects (Contd..1), H1 2016 105
Dormant Projects (Contd..2), H1 2016 106
Dormant Projects (Contd..3), H1 2016 107
Dormant Projects (Contd..4), H1 2016 108
Dormant Projects (Contd..5), H1 2016 109
Discontinued Products, H1 2016 110
List of Figures
Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Top 10 Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 26
Number of Products by Stage and Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Molecule Types, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 30
